Ombitasvir

Ombitasvir
Clinical data
Trade names	Viekira Pak, Viekira XR (with ombitasvir, paritaprevir, ritonavir and dasabuvir),; Technivie (with ombitasvir, paritaprevir, and ritonavir);
Other names	ABT-267
License data	EU EMA: by INN;
Routes of; administration	By mouth (tablets)
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	Not determined
Protein binding	~99.9%
Metabolism	Amide hydrolysis followed by oxidation
Onset of action	~4 to 5 hours
Elimination half-life	21 to 25 hours
Excretion	Mostly with feces (90.2%)
Identifiers
	IUPAC name Dimethyl N,N′-{[(2S,5S)-1-(4-tert-butylphenyl)pyrrolidene-2,5-diyl]-bis-{[(4,1-phenyleneazanediyl)carbonyl] [(2S)-pyrrolidine-2,1-diyl]}[(2S)-3-methyl-1-oxobutane-1,2-diyl])}biscarbamate;
CAS Number	1258226-87-7;
PubChem CID	54767916;
ChemSpider	31136214;
UNII	2302768XJ8;
KEGG	D10576 ;
ChEBI	CHEBI:85183 ;
CompTox Dashboard (EPA)	DTXSID201027920 ;
Chemical and physical data
Formula	C50H67N7O8
Molar mass	894.127 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc2ccc(cc2)[C@@H]3CC[C@H](N3c4ccc(cc4)C(C)(C)C)c5ccc(cc5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC;
	InChI InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1; Key:PIDFDZJZLOTZTM-KHVQSSSXSA-N;

Ombitasvir is an antiviral drug for the treatment of hepatitis C virus (HCV) infection by AbbVie. In the United States, it is approved by the Food and Drug Administration for use in combination with paritaprevir, ritonavir and dasabuvir in the product Viekira Pak for the treatment of HCV genotype 1,^[1]^[2] and with paritaprevir and ritonavir in the product Technivie for the treatment of HCV genotype 4.^[3]^[4]

Viekira Pak, Viekira XR (with ombitasvir, paritaprevir, ritonavir and dasabuvir),
Technivie (with ombitasvir, paritaprevir, and ritonavir)

Other namesABT-267

Quick facts Clinical data, Trade names ...

Close

Ombitasvir is an NS5A inhibitor that acts by inhibiting the HCV protein NS5A.^[5]

See also